Core Insights - The company announced that its self-developed innovative PD-1 inhibitor, Hanshuo® (Slulizumab), achieved the primary endpoint of event-free survival (EFS) in a Phase III clinical study for gastric cancer, marking a significant breakthrough in the field [1] Group 1: Clinical Study Results - The interim analysis by the independent data monitoring committee showed that the study met the predefined efficacy standards [1] - Hanshuo® combined with chemotherapy significantly improved EFS compared to placebo combined with chemotherapy, with a pathological complete response (pCR) rate more than three times that of the control group [1] - The treatment regimen demonstrated good safety, with no new safety signals identified [1] Group 2: Company Strategy and Future Plans - The CEO of the company emphasized that gastrointestinal tumors are a core area of focus for the company, and the achievement in the Phase III study represents a key breakthrough [1] - The company plans to actively promote the translation of these results to benefit patients and will continue to accelerate the exploration and application of more innovative therapies [1]
重大突破！复宏汉霖(2696.HK)H药胃癌围手术期III期临床研究达到主要终点 为该领域全球首个治疗方案